Search

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.

AACR Project GENIE steering committee head and Chair of MSK’s Human Oncology and Pathogenesis Program, Dr. Charles Sawyers, discusses how the first batch of genomic sequencing data fulfills an unmet need in oncology.

Scientists have learned that a drug activates a form of highly inflammatory programmed cell death called pyroptosis — a discovery that sheds light on immune function.

The risk of breast cancer increases as you age. MSK has breast cancer experts with special training and experience treating older patients.

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce that it is ranked among one of the top organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers published by the Institute for Scientific Information at Clarivate.

The DNA breaks that occur during meiosis are necessary but dangerous. Scientists now have a better handle on how cells control the chaos.

Meet molecular biologist Agnel Sfeir, who joined SKI's Molecular Biology Program in March 2021.

The 2016 GSK Experimental Therapeutics Symposium will be held at MSKCC this fall in continuation of the former Med into Grad Program.